Efficacy of SENS 401 in Subjects With Severe or Profound Sudden Sensorineural Hearing Loss

Related Clinical Trial
Appreciation for Music Processed by Hearing Aids Otoferlin Gene-Mediated Hearing Loss Natural History Study Implantation of the Cochlear™ Nucleus® Hybrid S Round Window (S-RW) in Adults Anatomy-Based Fitting in Unexperienced Cochlear Implant Users Effect of Modulated Auditory Stimulation on Interaural Auditory Perception Effect of Donepezil on Speech Recognition in Cochlear Implant Users Analysis of Risk Factors of Neurodevelopmental Disorder in Deaf Infants Under Ten Months of Age. Natural History in Children up to 10 Years With Moderate to Profound Hearing Loss Due to Mutations in GJB2/OTOF Genes Evaluation of Electrode-modiolus Distance and Cochlear Fibrosis Using Depth Sounding and Spectroscopy Tools Audiological and Quality of Life Outcomes of Anatomy Based Fitting in Patients Implanted by Robot Assisted Cochlear Implant Surgery (RACIS) Pupillometry Techniques Usage to Quantify the Programming Parameters Effect in the Auditory Effort in Zti Opticon Cochlear Implant Adult Users Factors Affecting Early Progress of Cochlear Implant Outcomes in Adults Study of Sound and Speech Perception in New Cochlear Implanted Subjects Using or Not an Anatomy-based Fitting Post Approval Study to Assure the ContInued saFety and effectIveness of Neuro Cochlear Implant System in Adult Users Quantification of Visually Evoked Cortical Potentials in Individuals With Hearing Loss A Trial of LY3056480 in Patients With SNLH Fundamental Asynchronous Stimulus Timing Sound Coding Study Phase I Clinical Study of HY01 in Patients Genotype-phenotype Correlation of SLC26A4 in CI Patients With EVA Study of Music and Speech Perception in New Cochlear Implanted Subjects Using or Not a Tonotopy Based Fitting Oral Statins and Protection From Hearing Loss Study of a Minimally Invasive Cochlear Access for Cochlear Implantation Via a Robotic Procedure Cochlear Implant With Dexamethasone Eluting Electrode Array Hearing Implant Performance in Adults With Low-Frequency Residual Hearing Perimodiolar Implant Performance in Adults With Low-Frequency Residual Hearing Cochlear Implanted Listening Effort and Hearing Attention The Performance of a Robot-assisted Minimally Invasive Direct Cochlear Access for Cochlear Implantation Auditory Performances With Different Stimulation Depths in Cochlear Implanted Subjects Using a Fine Structure Strategy Feasibility of the Mi2000 Totally Implantable Cochlear Implant in Severely to Profoundly Deaf Adults. Hearing Aid Noise Reduction in Pediatric Users Pilot Study (Oticon Pilot Study) Phase I/IIa Study Evaluating Safety and Efficacy of an Intratympanic Dose of PIPE-505 in Subjects With Hearing Loss Dexamethasone-Eluting Cochlear Implant Electrode Artificial Intelligence in Diagnosis of DFNA9 Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired Infants Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of HPN-07 and HPN-07 Plus NAC Cochlear Implant and Vestibular Function. Quality Control of CE-Certified Phonak Hearing Aids – 2018_42 Quality Control of CE-Certified Phonak Hearing Aids – 2018_28 Enlarged Vestibular Aqueduct Registry Evaluation of the High Frequency Digit Triplet Test in Cystic Fibrosis Effectiveness of P02 Digital Hearing Aids ABR Characteristics and Salivary Cortisone Concentration in Noise-exposed Workers Clinical Investigation of New CI Delivery Models in an Adult Nucleus CI Population Genetic Analysis of Hereditary Disorders of Hearing and Balance Compassionate Use Arm – ABI541 ABI for 10 NF2 Patients Evaluation of a Binaural Beamformer (StereoZoom) in a Virtual Acoustic Environment and in Real Life Evaluation of N6 Sound Processor in Group of Freedom Users Robotic Assisted Cochlear Implantation Feasibility Study Auditory Nerve Test System During Vestibular Schwannoma Resection Cochlear Electrical Impedance and the Effect of Topical Dexamethasone on Cochlear Implant Surgery Comparison Between Neuro 1 and Neuro 2 Cochlear Implant Speech Processors Listening Effort in Cochlear Implant Users Quality Control of CE-Certified Phonak Hearing Aids – 2019_19 Esteem Totally Implantable Hearing System A Clinical Trial of Anakinra for Steroid-Resistant Autoimmune Inner Ear Disease Study of Quality Perception on Music in New Cochlear Implanted Subjects Using or Not a Fine Structure Strategy An Evidence Based Delivery Model of Care for Newly Implanted Adult CI Recipients Study of Auditory Performance on Prosodic Tests in Cochlear Implanted Subjects Using a Fine Structure Strategy CI532 – Early Experience Study Clinical Applications of Round Window Imaging Anatomy in Cochlear Implant Surgery Single-sided Deafness and Cochlear Implants Cochlear Implantation Among Adults and Older Children With Unilateral or Asymmetric Hearing Loss Clinal Evaluation of Navigation Based Functional Ear Surgery Using Image Guided and Robotically Assisted Techniques OTO-413 in Subjects With Speech-in-Noise Hearing Impairment The Efficacy of a Minimally Invasive Direct Cochlear Access Via the HEARO Procedure Clinical Evaluation of a Cochlear Implant System Objective Measures in Cochlear Implant Evaluation of a Binaural Spatialization Method for Hearing Aids Esteem New Subject Enrollment Post Approval Study Safety of Autologous Stem Cell Infusion for Children With Acquired Hearing Loss Investigation of Anatomical Correlates of Speech Discrimination Efficacy of Digital Noise Reduction Strategies: A Hearing Aid Trial Evaluation of Revised Indicatons (ERID) for Cochlear Implant Candidacy for the Adult CMS Population Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts Balance in Children With Cochlear Implants Congenital Cytomegalovirus: Efficacy of Antiviral Treatment Nucleus Freedom Cochlear Implant System Pediatric Post-approval Study Evaluation of the Nucleus Hybrid™ L24 Cochlear Implant System Radiological Classification of the Facial Nerve Congenital Cytomegalovirus: Efficacy of Antiviral Treatment in a Randomized Controlled Trial The Effect of Sound Stimulation on Hearing Ability The Effect of Sound Stimulation on Pure-tone Hearing Threshold Efficacy of SENS 401 in Subjects With Severe or Profound Sudden Sensorineural Hearing Loss The SeaSHeL National Prospective Cohort Study Non-linear Frequency Compared to Conventional Processing in Patients With and Without Cochlear Dead Regions. Study of Low Level Laser Therapy and Word Recognition in Hearing Impaired Individuals Electrode Placement and Audiologic Outcomes With the Advanced Bionics HiFocus L23 Electrode Video HIT in Sudden Sensorineural Hearing Loss Determine the Incidence of Long QT Amongst a Large Cohort of Subjects Diagnosed With Unilateral or Bilateral Sensorineural Hearing Loss. FX-322 in Sensorineural Hearing Loss Autologous Bone Marrow Harvest and Transplant for Sensorineural Hearing Loss FX-322 in Adults With Stable Sensorineural Hearing Loss

Brief Title

Efficacy of SENS 401 in Subjects With Severe or Profound Sudden Sensorineural Hearing Loss

Official Title

A Two-part, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of SENS-401 in Subjects With Severe or Profound Sudden Sensorineural Hearing Loss

Brief Summary

      Primary objective of the study is to assess the efficacy of SENS-401 on hearing loss in
      comparison to placebo at the end of the 4-week treatment period

Detailed Description

      Patients will receive the study drug (SENS-401 or placebo) in the form of tablets by mouth,
      twice a day (3 tablets in the morning and 3 tablets in the evening), during the first 4 weeks
      after randomization.

      SENS-401 is an investigational medicinal product. It belongs to a family of drugs known as "5
      HT3 antagonist".

Study Phase

Phase 2/Phase 3

Study Type


Primary Outcome

Change in pure tone audiometry PTA (dB)


Severe Sudden Sensorineural Hearing Loss



Study Arms / Comparison Groups

 29 mg dose group
Description:  Patients will receive the study drug (SENS-401) in the form of tablets by mouth, twice a day, during the first 4 weeks after randomization.


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

February 15, 2019

Completion Date

January 12, 2022

Primary Completion Date

November 4, 2021

Eligibility Criteria

        The main criteria for inclusion:

          -  Male or female aged at least 18 years old

          -  Patients with unilateral idiopathic sudden sensorineural hearing loss or
             unilateral/bilateral acute acoustic trauma leading to sudden sensorineural hearing

          -  Patients with sudden hearing loss with onset within 96 hours prior to prior to first
             study drug intake.

          -  Patients under highly effective contraception

        The main criteria for exclusion:

          -  Bilateral idiopathic hearing loss

          -  Fluctuating hearing loss

          -  History of asymmetric hearing (>20 dB difference between ears) to the best knowledge
             of the patient

          -  Severe hearing loss (>90 dB) associated with unilateral (ipsilateral) complete
             vestibular loss.

          -  History of Ménière's disease, autoimmune hearing loss, radiation-induced hearing loss,
             acoustic neuroma (schwannoma), otosclerosis, suspected perilymph fistula or membrane
             rupture, suspected retro-cochlear lesion, or barotrauma

          -  Previous SSNHL in the affected ear within the past 6 weeks

          -  Complete loss of peripheral vestibular function on the affected side

          -  Any drug-based therapy for inner ear hearing loss that is ongoing or was performed in
             the past 6 weeks (except oral corticosteroids)

          -  Any ongoing or planned concomitant medication for the treatment of tinnitus until 6
             weeks after administration.

          -  Any therapy known as ototoxic (e.g. aminoglycosides, cisplatin, loop diuretics,
             quinine etc.) at the current time or in the past 6 months or planned in the coming 3

          -  Acute or chronic otitis media or otitis externa terminated less than 7 days

          -  Prior ear surgery of any kind (except ventilating tubes), or cochlear implants

          -  Known history of, or concomitant severe hepatic, gastrointestinal, cardiovascular,
             respiratory, neurological (except vertigo or tinnitus), hematological, renal,
             dermatological or psychiatric disease or substance abuse

          -  Neurological disorders including stroke, demyelinating disease, brain stem or
             cerebellar dysfunction within the last 3 months.

          -  Treatment with any investigational agent within 4 weeks or any past treatment with
             azasetron or with 5-HT3 antagonists, or any prior or planned treatment by
             antidepressant treatment containing serotoninergic agents.

          -  Patients with either a history of significant arrhythmia, or a history of conditions
             known to increase the proarrhythmic risk (e.g., congestive heart failure, long QT
             Syndrome, hypokalemia etc...).




18 Years - N/A

Accepts Healthy Volunteers



Géraldine HONNET, MD, , 

Location Countries


Location Countries


Administrative Informations



Organization ID

SENS 401-201

Responsible Party


Study Sponsor


Study Sponsor

Géraldine HONNET, MD, Study Director, Sensorion

Verification Date

January 2022